(NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the ...

Topline results were announced from a phase 3 study evaluating Moderna’s cytomegalovirus vaccine candidate, mRNA-1647.

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...

Moderna ($MRNA) stock jumped 17% on Thursday, fueled by speculation of potential buyout talks amid concerns over declining ...

Moderna announced in October 2025 that it will discontinue development of its investigational cytomegalovirus (CMV) vaccine, ...

A key question for investors going forward will be whether Moderna's other latent virus vaccines for Epstein-Barr and ...

Moderna halts late-stage CMV vaccine trial after unmet goals but maintains 2025 financial outlook. Read more here.

Moderna (MRNA) announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the company’s investigational ...